Mr. John Snisarenko reports

ZENTEK ANNOUNCES APPOINTMENT OF MOHAMMED JIWAN AS CHIEF EXECUTIVE OFFICER

Zentek Ltd. has appointed Mohammed (Moe) Jiwan as chief executive officer (CEO) and a director of the company, effective Dec. 1, 2025.

Mr. Jiwan joins Zentek with over 20 years of operational, capital markets and innovation leadership across public companies and high-growth ventures in technology, health care and life sciences. He has turned advanced technologies into scalable businesses and built organizations that deliver commercial value through disciplined execution and a deep understanding of regulated scientific and technology environments. Over his career, Mr. Jiwan has demonstrated an ability to secure and structure significant investment in the form of equity, senior debt and growth capital, and led major public company transactions that created substantial shareholder value. He has also driven multiple innovation awards, funding rounds and strategic M&A (mergers and acquisitions) outcomes.

"Today's announcement is more than a leadership transition; it marks the beginning of a disciplined transformation of our company," said John Snisarenko, chair of the board of Zentek. "Moe's extensive hands-on leadership and board-level advisory experience, coupled with a proven track record of significant shareholder value creation, position him to guide the company into its next phase of growth and on a trajectory toward long-term success."

"I am honoured and proud to lead the Zentek team and help unlock the value of the compelling opportunities we have before us," said Mr. Jiwan. "We are at a meaningful inflection point as a company, and our mandate now is to unlock the full value of our technologies and assets, secure the capital required to grow, and deliver on the commercial progress our shareholders deserve."

The board of directors thanks Wendy Ford, interim chief executive officer and chief financial officer, for her leadership and contributions during the CEO transition, and looks forward to her continued contributions as chief financial officer.

The company further announces that it has granted effective Nov. 25, 2025, to certain officers, directors and consultants of the company, (i) stock options to acquire an aggregate of 475,000 common shares at a price of $1.06 per common share for a period of three years, vesting for officers and directors one-third on the date of grant, one-third on Dec. 1, 2026, and one-third on Dece. 1, 2027; and (ii) an aggregate of 425,000 restricted share units vesting on Dec. 1, 2026. The securities issued to officers and directors of the company are subject to a four-month hold period from the date of grant.

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer and greener.

Zentek's patented technology platform ZenGuard is shown to have enhanced viral filtration efficiency for surgical masks and HVAC (heating, ventilation and air conditioning) systems. Zentek's ZenGuard production facility is in Guelph, Ont.

We seek Safe Harbor.